Prospective Multi-Center Observational Study to Assess Persistence, Adherence and Changes in Disease Activity in the Children Population of Juvenile Arthritis Patients Treated With Adalimumab (HUMIRA) in the Routine Clinical Settings in the Russian Federation
Not yet recruiting
Phase of Trial: Phase IV
Latest Information Update: 21 Mar 2018
At a glance
- Drugs Adalimumab (Primary)
- Indications Juvenile rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors AbbVie
- 14 Mar 2018 Planned number of patients changed from 100 to 70.
- 14 Mar 2018 Planned End Date changed from 30 Dec 2019 to 31 Mar 2020.
- 14 Mar 2018 Planned primary completion date changed from 30 Dec 2019 to 31 Mar 2020.